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CLINICAL HISTORY
The patient is a 66-year-old female who 
presented with a left supraclavicular 
mass (5.7 cm on ultrasound).  An 
MRI scan (Fig.1) was performed and 
confirmed a mass displacing the left 
sternocleidomastoid muscle anteriorly 
with mixed cystic and solid appearance. 
CT scan of the chest and abdomen did 
not show additional lymphadenopathy. 
The patient reported history of chronic 
fatigue, and a remote history of right 
nephrectomy.  A CBC was unremarkable 
except for a chronic normocytic anemia 
with hemoglobin of 10.4 g/dL. 
HISTOLOGIC FINDINGS
Histologic sections revealed a well-circumscribed, mostly encapsulated 
tumor composed of spindle to ovoid cells, which in areas formed 
whorls, particularly around small vessels (Fig. 2A, 2B).  The tumor cells 
showed indistinct cell borders and nuclei with vesicular to granular 
chromatin, variably prominent nucleoli, occasional multinucleation, and 
scattered pseudo-nuclear inclusions.  There was significant cytologic 
atypia/pleomorphism (Fig. 2C).  Areas of necrosis were noted (Fig. 
2D). Perivascular lymphocyte aggregation was also seen. The mitotic 
count ranged from 4 to 9 mitoses per 10 high power fields.
An extensive panel of immunostains was performed (Fig. 3) and 
revealed that the tumor cells were strongly and diffusely positive 
for vimentin, CD21, CD35, CD23, and showed patchy membranous 
staining with D240.  The tumor cells were negative immunostains for 
CD1a, AE1/3, EMA, CD45, CD20, CD3, CD4, CD8, CD34, CD56, CD68, 





Follicular dendritic cell sarcoma (FDCS)  is a neoplastic proliferation of spindled to 
ovoid follicular dendritic cells.  This neoplasm is rare with wide age spectrum.  The 
median age of patients according to one study was 48 years, and they had an equal 
sex distribution. Cervical lymph nodes are the most common site.  However disease 
can present extranodally. Patients usually present with slowly growing painless 
mass.  Systemic symptoms are uncommon.   The morphology is that of spindle to 
ovoid cells forming fascicles, storiform arrays / whorls around blood vessels, diffuse 
sheets and vague nodularity. The mitotic rate is usually between 0 and 10/ 10 high-
power fields (HPF). The more pleomorphic cases demonstrate a higher mitotic 
rates (>30/ 10 HPF). Nuclear atypia is highly variable.  Necrosis and hemorrhage 
can be seen. The Immunophenotype is always positive for one or more of the FDC 
markers such as CD21, CD45, CD23 and CD35. The tumor is variably positive for 
CD68, S100 and negative for CD1a. The behavior is usually indolent. High-grade 
features such as overt cytologic atypia, extensive coagulative necrosis and a high 
proliferative index, and large tumour size or intraabdominal location are associated 
with an adverse prognosis. No prospective studies of treatments and outcomes 
in patients with FDCS have been reported which make it difficult to provide firm 
treatment recommendations. However, most patients are treated by complete 
surgical excision, with or without adjuvant radiotherapy or chemo -therapy. Local 
recurrences occur in more than 50% of cases, and metastases occur in about 25% 
of patients. Our case presented with unifocal disease and therefore was treated with 
excision and radiation therapy. No further clinical follow up on this patient as of this 
time to evaluate further response. 
2A 2B
2C 2D
3A:	CD21 3B:	CD35
3D:	CD1a3C:	CD23
